Clinical Trial

Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors

Study acronym: MESRIX-more
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Dry mouth leads to debilitating symptoms 24/7. The two primary causes for dry mouth are Sjögrens disease and after radiotherapy of a head and neck cancer. Former clinical trials have investigated mesenchymal stem cell treatment for dry mouth with promising results. However, few of the participants evolved normal salivary flow rate. Therefore, in this randomized clinical trial, two treatments of mesenchymal stem cells are administered, 4 months apart. This has not been done before. The hypothesis is that two treatments of mesenchymal stem cells results in a higher salivary flow rate and ameliorate symptoms from dry mouth.
Trial Details
NCT Number NCT07290946
Lead Sponsor Christian von Buchwald
Conditions Xerostomia Due to Hyposecretion of Salivary Gland, Xerostomia Due to Radiotherapy, Sjögren´s Syndrome
Enrollment 100 participants
Start Date 2025-12
Primary Completion 2027-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-18